Does CD47 expression have prognostic significance in classical Hodgkin lymphoma?

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Hodgkin lymphoma (HL) requires novel therapies for relapsed or refractory cases.
• CD47 acts as an antiphagocytic signal via the SIRPα pathway on macrophages.
• Understanding CD47 expression in HL is crucial for potential therapeutic targeting.

Purpose of the Study:

• To evaluate CD47 expression in classical Hodgkin lymphoma (cHL) cells.
• To investigate the association between CD47 expression and Epstein-Barr virus (EBV) status.
• To explore the relationship between CD47 expression and the International Prognostic Index (IPI) in HL patients.

Main Methods:

• Immunohistochemistry was used to assess CD47 expression in Hodgkin and Reed-Sternberg (HRS) cells from 120 cHL patients.
• CD47 expression scores were calculated based on prevalence and intensity.
• Patient data, including demographic information, EBV status, and IPI scores, were analyzed.

Main Results:

• CD47 was broadly expressed in HRS cells across the cohort.
• No statistically significant correlation was found between CD47 expression scores and age, sex, EBV status, or IPI scores.
• A significant association was observed between higher IPI scores and increased EBV positivity (p=0.041).

Conclusions:

• CD47 exhibits widespread expression in classical Hodgkin lymphoma.
• Current findings do not support a significant relationship between CD47 expression and key clinical parameters in HL.
• Further investigation is warranted to determine the clinical utility of CD47 as a biomarker in HL.